1599 related articles for article (PubMed ID: 33536322)
1. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model.
Hutson CL; Kondas AV; Mauldin MR; Doty JB; Grossi IM; Morgan CN; Ostergaard SD; Hughes CM; Nakazawa Y; Kling C; Martin BE; Ellison JA; Carroll DS; Gallardo-Romero NF; Olson VA
mSphere; 2021 Feb; 6(1):. PubMed ID: 33536322
[TBL] [Abstract][Full Text] [Related]
2. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge.
Russo AT; Berhanu A; Bigger CB; Prigge J; Silvera PM; Grosenbach DW; Hruby D
Vaccine; 2020 Jan; 38(3):644-654. PubMed ID: 31677948
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease.
Trost LC; Rose ML; Khouri J; Keilholz L; Long J; Godin SJ; Foster SA
Antiviral Res; 2015 May; 117():115-21. PubMed ID: 25746331
[TBL] [Abstract][Full Text] [Related]
4. Drug Development against Smallpox: Present and Future.
Delaune D; Iseni F
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932370
[TBL] [Abstract][Full Text] [Related]
5. Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.
Crump R; Korom M; Buller RM; Parker S
Antiviral Res; 2017 Mar; 139():112-116. PubMed ID: 28039021
[TBL] [Abstract][Full Text] [Related]
6. New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus.
DeLaurentis CE; Kiser J; Zucker J
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0122622. PubMed ID: 36374026
[TBL] [Abstract][Full Text] [Related]
7. The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak.
Foster SA; Parker S; Lanier R
Viruses; 2017 Oct; 9(11):. PubMed ID: 29773767
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans.
Leeds JM; Fenneteau F; Gosselin NH; Mouksassi MS; Kassir N; Marier JF; Chen Y; Grosenbach D; Frimm AE; Honeychurch KM; Chinsangaram J; Tyavanagimatt SR; Hruby DE; Jordan R
Antimicrob Agents Chemother; 2013 Mar; 57(3):1136-43. PubMed ID: 23254433
[TBL] [Abstract][Full Text] [Related]
9. A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus.
Stabenow J; Buller RM; Schriewer J; West C; Sagartz JE; Parker S
J Virol; 2010 Apr; 84(8):3909-20. PubMed ID: 20130052
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbits.
Grossi IM; Foster SA; Gainey MR; Krile RT; Dunn JA; Brundage T; Khouri JM
Antiviral Res; 2017 Jul; 143():278-286. PubMed ID: 28392420
[TBL] [Abstract][Full Text] [Related]
11. In vitro efficacy of brincidofovir against variola virus.
Olson VA; Smith SK; Foster S; Li Y; Lanier ER; Gates I; Trost LC; Damon IK
Antimicrob Agents Chemother; 2014 Sep; 58(9):5570-1. PubMed ID: 24957837
[TBL] [Abstract][Full Text] [Related]
12. Oral Tecovirimat for the Treatment of Smallpox.
Grosenbach DW; Honeychurch K; Rose EA; Chinsangaram J; Frimm A; Maiti B; Lovejoy C; Meara I; Long P; Hruby DE
N Engl J Med; 2018 Jul; 379(1):44-53. PubMed ID: 29972742
[TBL] [Abstract][Full Text] [Related]
13. Treatment and Vaccination for Smallpox and Monkeypox.
Saalbach KP
Adv Exp Med Biol; 2024; 1451():301-316. PubMed ID: 38801586
[TBL] [Abstract][Full Text] [Related]
14. [THE USE OF THE MODEL MOUSE ICR--VARIOLA VIRUS FOR EVALUATION OF ANTIVIRAL DRUG EFFICACY].
Titova KA; Sergeev AA; Kabanov AS; Bulychev LE; Sergeev AA; Galakhova DO; Shishkina LN; Zamedyanskaya AS; Nesterov AE; Glotov AG; Taranov OS; Omigov VV; Agafonov AP; Sergeev AN
Vopr Virusol; 2016; 61(2):79-84. PubMed ID: 27451500
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.
Parker S; Chen NG; Foster S; Hartzler H; Hembrador E; Hruby D; Jordan R; Lanier R; Painter G; Painter W; Sagartz JE; Schriewer J; Mark Buller R
Antiviral Res; 2012 Apr; 94(1):44-53. PubMed ID: 22381921
[TBL] [Abstract][Full Text] [Related]
16. A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge.
Parker S; D'Angelo J; Buller RM; Smee DF; Lantto J; Nielsen H; Jensen A; Prichard M; George SL
Antiviral Res; 2021 Nov; 195():105179. PubMed ID: 34530009
[TBL] [Abstract][Full Text] [Related]
17. Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox.
Chittick G; Morrison M; Brundage T; Nichols WG
Antiviral Res; 2017 Jul; 143():269-277. PubMed ID: 28093339
[TBL] [Abstract][Full Text] [Related]
18. Antivirals With Activity Against Mpox: A Clinically Oriented Review.
Siegrist EA; Sassine J
Clin Infect Dis; 2023 Jan; 76(1):155-164. PubMed ID: 35904001
[TBL] [Abstract][Full Text] [Related]
19. The highly virulent variola and monkeypox viruses express secreted inhibitors of type I interferon.
Fernández de Marco Mdel M; Alejo A; Hudson P; Damon IK; Alcami A
FASEB J; 2010 May; 24(5):1479-88. PubMed ID: 20019241
[TBL] [Abstract][Full Text] [Related]
20. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection.
Stittelaar KJ; Neyts J; Naesens L; van Amerongen G; van Lavieren RF; Holý A; De Clercq E; Niesters HG; Fries E; Maas C; Mulder PG; van der Zeijst BA; Osterhaus AD
Nature; 2006 Feb; 439(7077):745-8. PubMed ID: 16341204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
